Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Purified
Block
Synthetic
This peptide is soluble in PBS and water. After reconstitution keep at -20°C. Avoid repetitive freeze/thaw cycles.
Lyophilized
> 90% purity
Control Peptide. This peptide may be used to block the binding activity of antibodies to alpha synuclein (see antibodies catalog # S-024-100 and S-075-50).
For research use only.
United States
12 months after date of receipt (unopened vial).
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
